Strengthening U.S. Pharmaceutical Supply: SCHOTT Pharma Inaugurates Expanded Vial Production in Lebanon, PA
SCHOTT Pharma inaugurates new capacity for core and specialty vials at its site in Lebanon, PA, supporting future growth in the region.
Over 60 million USD investment supported by the Biomedical Advanced Research and Development Authority (BARDA) strengthens the U.S. domestic medical supply chain and enables rapid response in case of public health emergencies.
The state-of-the-art equipment sets new quality and automation standards for high-value solutions (HVS) in the U.S.
SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs – from biologics and other complex injectable therapies to vaccines and emergency room medications. The new capabilities feature state-of-the-art technology for efficient manufacturing and optimized output. The over 60 million USD investment was largely funded by the Biomedical Advanced Research and Development Authority (BARDA) to strengthen the resilience of the U.S. pharmaceutical supply chain and ensure reliable domestic production of critical primary packaging. The expansion significantly increases the site’s annual production capacity for core vials, while more than tripling local capacity for high-value solutions.
